Farms.com Home   News

High-oleic sunflower production comes up short

High-oleic sunflower production is way down in Ukraine, and that presents a marketing opportunity for Canada’s high-oleic canola growers, says an industry official.

UkrAgroConsult is reporting that Ukraine’s high-oleic sunflower acres are down 55 percent in 2022-23 compared to last year. The country’s sunflower harvest is just wrapping up.

Ukraine is the world’s leading supplier of high-oleic sunflower oil, followed by Russia.

John Jansen, vice-president of strategic partnerships with the United Soybean Board (USB), said his contacts in Europe don’t think the situation is as dire as UkrAgroConsult is reporting.

“We don’t forecast anywhere near 50 (percent),” he said.

“Maybe we are behind the curve on that or don’t have the appropriate visibility.”

The USB believes acres are down about 15 percent compared to normal in Ukraine, and exports may be about 20 percent below the usual volumes.

However, he noted that exports out of Russia are also expected to be down about 30 percent due to international sanctions, so combined it’s still a big blow to the global supply of high-oleic oils.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.